Certara, Inc. has solidified its position as a leader in biosimulation science and technology, delivering operating profitability in 2025 after several years of losses. The company’s growth is supported by its comprehensive Model-Informed Drug Development (MIDD) platform, AI-enabled regulatory software, and extensive scientific consulting services. With over 2,600 life sciences customers and market penetration among top biopharmaceutical companies and regulators, Certara is expanding both organically and through strategic acquisitions, though challenges remain in regulatory complexity and competitive pressures. Financially, the company generated strong cash flow and implemented capital returns through share buybacks in 2025.